Beyond Allergies—Updates on The Role of Mas-Related G-Protein-Coupled Receptor X2 in Chronic Urticaria and Atopic Dermatitis

Mast cells (MCs) are an important part of the immune system, responding both to pathogens and toxins, but they also play an important role in allergic diseases, where recent data show that non-IgE-mediated activation is also of relevance, especially in chronic urticaria (CU) and atopic dermatitis (A...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Cells (Basel, Switzerland) Ročník 13; číslo 3; s. 220
Hlavní autori: Lerner, Liron, Babina, Magda, Zuberbier, Torsten, Stevanovic, Katarina
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Switzerland MDPI AG 01.01.2024
Predmet:
Allergic diseases
Allergies
Atopic dermatitis
Care and treatment
Chronic Urticaria - drug therapy
Degranulation
Dermatitis
Dermatitis, Atopic - drug therapy
Dermatitis, Atopic - metabolism
Drugs
G protein-coupled receptors
Health care
Humans
Hypersensitivity - metabolism
Immune system
Immunoglobulin E
Investigations
Mast cells
Mast Cells - metabolism
MRGPRX2
Nerve Tissue Proteins - metabolism
Pathogenesis
Pathophysiology
Physiological aspects
Proteins
Receptors, G-Protein-Coupled - metabolism
Receptors, Neuropeptide - metabolism
Skin diseases
skin mast cells
Therapeutic targets
Urticaria
Germany
skin mast cells
atopic dermatitis
MRGPRX2
urticaria
ISSN:2073-4409, 2073-4409
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Mast cells (MCs) are an important part of the immune system, responding both to pathogens and toxins, but they also play an important role in allergic diseases, where recent data show that non-IgE-mediated activation is also of relevance, especially in chronic urticaria (CU) and atopic dermatitis (AD). Skin MCs express Mas-related G-protein-coupled receptor X2 (MRGPRX2), a key protein in non-IgE-dependent MC degranulation, and its overactivity is one of the triggering factors for the above-mentioned diseases, making MRGPRX2 a potential therapeutic target. Reviewing the latest literature revealed our need to focus on the discovery of MRGPRX2 activators as well as the ongoing vast research towards finding specific MRGPRX2 inhibitors for potential therapeutic approaches. Most of these studies are in their preliminary stages, with one drug currently being investigated in a clinical trial. Future studies and improved model systems are needed to verify whether any of these inhibitors may have the potential to be the next therapeutic treatment for CU, AD, and other pseudo-allergic reactions.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2073-4409
2073-4409
DOI:10.3390/cells13030220